Research programme: TGFb/retinol nanocapsules - TherapyX

Drug Profile

Research programme: TGFb/retinol nanocapsules - TherapyX

Alternative Names: TGFβ-NanoCap®

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator TherapyX
  • Class Antineoplastics; Antivirals; Growth factors; Nootropics; Retinoids; Transforming growth factors
  • Mechanism of Action Transforming growth factor beta type I receptor modulators; Vitamin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 27 Jul 2016 Preclinical trials in Inflammatory bowel disease in USA (PO)
  • 27 Jul 2016 Research programme: TGFb/retinol nanocapsules - TherapyX is available for licensing -
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top